Research Topics
Genomes and GenesSpecies | Bertrand RochatSummaryAffiliation: Centre Hospitalier Universitaire Vaudois Country: Switzerland Publications
| Collaborators
|
Detail Information
Publications
Role of cytochrome P450 activity in the fate of anticancer agents and in drug resistance: focus on tamoxifen, paclitaxel and imatinib metabolismBertrand Rochat
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Clin Pharmacokinet 44:349-66. 2005..e. drug dosage and selection. In addition, a more complete understanding of the metabolism of anticancer agents will assist in the prediction of drug-drug interactions, as anticancer agent combinations are becoming more prevalent...- Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosingBertrand Rochat
Quantitative Mass Spectrometry Facility, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, CH 1011 Lausanne, Switzerland
Antimicrob Agents Chemother 54:5074-81. 2010..5 ?g/ml. The UPLC-MS/MS method and sensitive bioassay offer alternative tools for accurate and precise quantification of the plasma concentrations in patients receiving oral posaconazole... - Liquid chromatography-mass spectrometry method for quantification of caspofungin in clinical plasma samplesBertrand Rochat
Quantitative Mass Spectrometry Facility, Faculty of Biology and Medicine, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
J Mass Spectrom 42:440-9. 2007..Mean intra- and inter-day precision was 7.9 +/- 3.2% and 6.3 +/- 1.8%, respectively. This simple and robust liquid chromatography-tandem mass spectrometry (LC-MS/MS) method may easily be implemented for monitoring CASPO therapy... - In vitro biotransformation of imatinib by the tumor expressed CYP1A1 and CYP1B1Bertrand Rochat
Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
Biopharm Drug Dispos 29:103-18. 2008..They could play a role in imatinib disposition in the targeted stem, progenitor and differentiated cancer cells, with a possible contribution of the metabolites toward the activity of the drug... - Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometryBertrand Rochat
Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois CHUV, 1011 Lausanne, Switzerland
J Mass Spectrom 43:736-52. 2008..This article underscores that, in addition to usual therapeutic drug monitoring (TDM), LC-MS/MS methods can simultaneously record a complete drug metabolic profile enabling various correlation studies of clinical interest... - Importance of influx and efflux systems and xenobiotic metabolizing enzymes in intratumoral disposition of anticancer agentsB Rochat
Dépatment Formation et Recherche, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
Curr Cancer Drug Targets 9:652-74. 2009..Indeed, inhibition of tumor expressed metabolizing enzymes could strongly increase drug disposition, specifically in the target cells resulting in more efficient therapies... - Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspoLaurent Arthur Decosterd
Division of Clinical Pharmacology, Department of Medicine, BH18, Lab 218 226, Centre Hospitalier Universitaire Vaudois and University of Lausanne, CH 1011 Lausanne, Switzerland
Antimicrob Agents Chemother 54:5303-15. 2010.... - Fragmentation study of imatinib and characterization of new imatinib metabolites by liquid chromatography-triple-quadrupole and linear ion trap mass spectrometersMarc Marull
Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, 1011 Lausanne, Switzerland
J Mass Spectrom 41:390-404. 2006..Various MS(n) product scans (n < or = 4) were acquired on the linear ion trap or on the triple-quadrupole MS. Postulated structures of new metabolites are addressed... - Comparison between a linear ion trap and a triple quadruple MS in the sensitive detection of large peptides at femtomole amounts on columnBilgin Vatansever
Quantitative Mass Spectrometry Facility, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
J Sep Sci 33:2478-88. 2010..Indeed, with the three longer peptides, the typical fragmentation in the TQ-MS resulted in a dramatic loss of sensitivity (> or = 10x)... - Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikreinKarim Abid
Division of Clinical Pharmacology and Toxicology, Centre Hospitalier Universitaire Vaudois CHUV, 1011 Lausanne, Switzerland
J Biol Chem 284:24715-24. 2009..Receptor binding assays revealed that NPY(3-35) is unable to bind to NPY Y1, Y2, and Y5 receptors; thus NPY(3-35) may represent the major metabolic clearance product of the Y2/Y5 agonist, NPY(3-36)... - Generic approach for the sensitive absolute quantification of large undigested peptides in plasma using a particular liquid chromatography-mass spectrometry setupHamid Reza Sobhi
Quantitative Mass Spectrometry Facility, University Hospital of Lausanne, CHUV, BH18 228, 1011 Lausanne, Switzerland
J Chromatogr A 1218:8536-43. 2011..This generic approach can be applied for the determination of most therapeutic peptides and possibly for endogenous peptides with latest state-of-the-art instruments... - Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long termMarkus Neef
Institute of Clinical Pharmacology, University of Berne, Berne, Switzerland
J Hepatol 44:167-75. 2006..CONCLUSIONS: The antifibrotic effectiveness of imatinib is limited to the early phase of fibrogenesis. In ongoing liver injury other mediators most likely compensate for the inhibited PDGF effect...